Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs by Boretti, F S et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Comparison of 2 doses of recombinant human thyrotropin for
thyroid function testing in healthy and suspected hypothyroid
dogs.
Boretti, F S; Sieber-Ruckstuhl, N S; Wenger-Riggenbach, B; Gerber, B; Lutz, H;
Hofmann-Lehmann, R; Reusch, C E
Boretti, F S; Sieber-Ruckstuhl, N S; Wenger-Riggenbach, B; Gerber, B; Lutz, H; Hofmann-Lehmann, R; Reusch, C
E (2009). Comparison of 2 doses of recombinant human thyrotropin for thyroid function testing in healthy and
suspected hypothyroid dogs. Journal of Veterinary Internal Medicine, 23(4):856-861.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Veterinary Internal Medicine 2009, 23(4):856-861.
Boretti, F S; Sieber-Ruckstuhl, N S; Wenger-Riggenbach, B; Gerber, B; Lutz, H; Hofmann-Lehmann, R; Reusch, C
E (2009). Comparison of 2 doses of recombinant human thyrotropin for thyroid function testing in healthy and
suspected hypothyroid dogs. Journal of Veterinary Internal Medicine, 23(4):856-861.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Veterinary Internal Medicine 2009, 23(4):856-861.
Comparison of 2 doses of recombinant human thyrotropin for
thyroid function testing in healthy and suspected hypothyroid
dogs.
Abstract
BACKGROUND: Various protocols using different doses of recombinant human thyrotropin (rhTSH)
in TSH stimulation testing have been described. However, the influence of TSH dosage on thyroxine
(T4) concentration has not yet been evaluated in suspected hypothyroid dogs. OBJECTIVE: To evaluate
the effectiveness of 2 doses of rhTSH. ANIMALS: Fifteen dogs with clinical signs consistent with
hypothyroidism and abnormal stimulation results with 75 microg rhTSH and 18 clinically healthy dogs.
METHODS: All dogs were stimulated with 75 and 150 microg rhTSH IV in a 1st and 2nd stimulation
test, respectively. Blood samples were taken before and 6 hours after rhTSH administration for
determination of total T4 concentration. RESULTS: Using the higher dose led to a normal test
interpretation in 9 of the 15 dogs, in which stimulation had been abnormal using the lower dose. Based
on follow-up information, hypothyroidism was excluded in 7 of these 9 dogs. In all 6 dogs with a
blunted response to the higher dose, hypothyroidism could be confirmed. Healthy dogs showed
significantly higher post-TSH T4 concentrations with the higher compared with the lower dose.
Post-TSH T4 concentrations after TSH stimulation were not related to dogs' body weight in either
healthy or diseased dogs. CONCLUSIONS AND CLINICAL RELEVANCE: TSH dose significantly
influenced test interpretation in suspected hypothyroid dogs. Differentiation between primary
hypothyroidism and nonthyroidal disease was improved with 150 microg rhTSH. Because this effect
was independent of the dogs' body weight, the higher dose is recommended in dogs that have concurrent
disease or are receiving medication.
Comparison of 2 Doses of Recombinant Human Thyrotropin
for Thyroid Function Test ing in Healthy and Suspected
Hypothyroid Dogs
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Background: Various protocols using different doses of recombinant human thyrotropin (rhTSH) in TSH stimulation test-
ing have been described. However, the inﬂuence of TSH dosage on thyroxine (T4) concentration has not yet been evaluated in
suspected hypothyroid dogs.
Objective: To evaluate the effectiveness of 2 doses of rhTSH.
Animals: Fifteen dogs with clinical signs consistent with hypothyroidism and abnormal stimulation results with 75mg
rhTSH and 18 clinically healthy dogs.
Methods: All dogs were stimulated with 75 and 150mg rhTSH IV in a 1st and 2nd stimulation test, respectively. Blood
samples were taken before and 6 hours after rhTSH administration for determination of total T4 concentration.
Results: Using the higher dose led to a normal test interpretation in 9 of the 15 dogs, in which stimulation had been ab-
normal using the lower dose. Based on follow-up information, hypothyroidism was excluded in 7 of these 9 dogs. In all 6 dogs
with a blunted response to the higher dose, hypothyroidism could be conﬁrmed. Healthy dogs showed signiﬁcantly higher post-
TSH T4 concentrations with the higher compared with the lower dose. Post-TSHT4 concentrations after TSH stimulation were
not related to dogs’ body weight in either healthy or diseased dogs.
Conclusions and Clinical Relevance: TSH dose signiﬁcantly inﬂuenced test interpretation in suspected hypothyroid dogs.
Differentiation between primary hypothyroidism and nonthyroidal disease was improved with 150 mg rhTSH. Because this
effect was independent of the dogs’ body weight, the higher dose is recommended in dogs that have concurrent disease or are
receiving medication.
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A lthough hypothyroidism is one of the most commonendocrinopathies in dogs, its diagnosis still can be
challenging. Determination of serum thyroxine concen-
tration (T4) is accepted as a primary screening test
because of its good diagnostic sensitivity, but its speciﬁc-
ity is low because it is inﬂuenced not only by non-
thyroidal disease but also by many drugs. In contrast to
the situation in human medicine, the low sensitivity of
endogenous thyrotropin (TSH) so far has precluded its
use as a reliable diagnostic test in veterinary medicine.1–3
The TSH stimulation test has long been considered an
accurate test, and some authors still recognize it as the
‘‘gold standard’’ for conﬁrming the diagnosis of canine
hypothyroidism.4 Determination of circulating T4 before
and after administration of exogenous TSH provides an
assessment of the functional reserve capacity of the thy-
roid gland, with minimal to no stimulation expected in
hypothyroidism. The test seems to be less inﬂuenced by
nonthyroidal illness and medications known to affect
thyroid function.4 Because the traditionally used bovine
TSH (bTSH) is no longer commercially available as a
pharmaceutical preparation, a number of protocols with
recombinant human TSH (rhTSH) have been proposed
for TSH stimulation testing in dogs.5–8 In the 1st study
evaluating rhTSH in healthy Beagles, the authors pro-
posed a dose of 50 mg rhTSH per dog.8 Additional studies
used higher doses (75 and 91mg)7,9 or doses based on the
dogs’ body weight, with 50 mg for dogs below 29 kg and
100mg rhTSH for dogs above 29 kg.10 Because the cost of
rhTSH is high, using a lower dose would be helpful in
decreasing the overall expense of TSH stimulation testing
and make the test useful for veterinarians in private prac-
tice. On the other hand, using a lower dose could lead to
less than maximal stimulation in a dog with nonthyroidal
disease, which in turn could result in misdiagnosis and
unnecessary treatment of a euthyroid dog. In situations
in which testing cannot be delayed or in which medica-
tion cannot be withdrawn, knowledge of the optimal
dose to clearly differentiate between primary hypothy-
roidism and nonthyroidal disease would be a prerequisite
for performing the test. However, the inﬂuence of rhTSH
dose so far has not been systematically evaluated in dis-
eased dogs.
Consequently, the purpose of the present study was to
evaluate the effectiveness of 2 doses of rhTSH to assess
thyroid function in dogs, in which hypothyroidism
was suspected. Therefore, dogs in which stimulation
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with 75 mg rhTSH had been considered abnormal were
restimulated a 2nd time with 150mg rhTSH. In addition,
healthy, body weight-matched control dogs were stimu-
lated with both doses to assess a possible inﬂuence of
body weight on magnitude of stimulation.
Materials and Methods
Dogs Suspected of Having Hypothyroidism
Dogs that had been presented or referred to the Clinic for Small
Animal Internal Medicine of the University of Zurich for investiga-
tion of clinical signs consistent with hypothyroidism underwent a
1st TSH stimulation test (1st stimulation). Results of stimulation
tests were interpreted with criteria established in 38 healthy dogs.6
On the basis of these criteria, dogs were assigned to 1 of 3 groups,
depending on whether they showed normal, no, or intermediate
stimulation. A normal stimulation was deﬁned as a post-TSH T4 of
2.5mg/dL and at least 1.5 times the basal T4 concentration. Dogs
with a post-TSH T4 of o1.6 mg/dL and o1.5 times the basal T4
concentration were considered to have no stimulation. Dogs with a
post-TSH T4 between 1.6 and 2.5 or post-TSH T4 values of
2.5mg/dL, but an increase ofo1.5 times basal T4 was considered
to have an intermediate stimulation.
Dogs were included in the present study if the 1st stimulation was
considered abnormal (no or intermediate stimulation) and if owners
agreed to a 2nd stimulation. A total of 15 dogs with a median
(range) age of 6 years (2–12 years) and a median (range) body
weight of 32 kg (18–104 kg) fulﬁlled the inclusion criteria. The most
common complaints, either alone or in combination, were exercise
intolerance, dermatologic problems, and weight gain. Medication
history included, either alone or in combination, glucocorticoids
(prednisolone, 0.2–1.5mg/kg q12h for 8–12 weeks; hydrocortisone
spray for 4 weeks), mineralocorticoids (ﬂudrocortisones for 12
weeks), nonsteroidal anti-inﬂammatory drugs (NSAIDS; carprofen
for 2–4 months), antibiotics (cephalosporin for 8 weeks; amoxicillin/
clavulanic acid for 2 weeks), trilostane, ACE inhibitor (benazepril),
xanthine oxidase inhibitor (allopurinol), H2-receptor antagonist
(ranitidine), and sucralfate in 12 of the 15 dogs. Previously or con-
currently diagnosed and treated diseases included megaesophagus
(1 dog), hypoadrenocorticism (1 dog), hyperadrenocorticism (1 dog),
and chronic leishmaniasis (1 dog). All dogs underwent a 2nd stimu-
lation at twice the original rhTSH dose. In selected dogs, a 3rd
stimulation was performed, again with the original dose.
Healthy Dogs
Eighteen healthy privately owned dogs that were age- and body
weight-matched to the suspected hypothyroid dogs were included.
They had a median (range) age of 6 years (2–12 years) and a median
body weight of 34 kg (21–67kg). All dogs were determined to be
healthy and euthyroid on the basis of their history and results of a
physical examination, CBC, serum biochemical proﬁle, serum total
thyroxine (T4) concentration, and serum canine TSH (cTSH) con-
centration. None of the dogs had received any medication for at
least 8 weeks before stimulation.
TSH Stimulation Tests
TSH stimulation tests were performed with rhTSHa injected IV
at a dose of 75 mg (1st stimulation). All dogs received a higher dose
of rhTSH, which was twice the original dose (150mg rhTSH IV, 2nd
stimulation). Blood samples (jugular venipuncture) were collected
immediately before and 6 h after administration of rhTSH. After
clot retraction at room temperature, serum was harvested by low-
speed centrifugation and transferred to tubes for storage at 201C
for later hormone assay. Informed consent of all pet owners was
obtained before the tests were performed.
In the 15 suspected hypothyroid dogs, the 2nd stimulation was
performed after a median (range) of 9 days (5–231) after the 1st
stimulation, whereas in the healthy dogs stimulation was repeated
within 7–20 days (median 10 days) after the 1st stimulation.
Analytical Procedures
Serum T4 was measured by use of a commercially available solid
phase, chemiluminescent enzyme immunoassayb validated for use in
dogs; intraassay and interassay coefﬁcients of variation (6 T4 con-
centrations, 0.65–11.9mg/dL; each concentration tested in duplicate
twice daily over the course of 20 days) were 3.9–10.8 and 5.2–13.8%,
respectively (reference range, 1.5–5.0mg/dL). Serum cTSH concen-
trations were determined in prestimulation samples on the day of
the 1st TSH stimulation by use of a solid part, 2-site chemilumines-
cent enzyme immunometric assayc validated for use in dogs (upper
limit of the reference range, 0.6 ng/mL).
Statistical Analyses
Data were analyzed with nonparametric statistical methods.d,e
Wilcoxon’s matched pairs, Friedman’s repeated measures test for
paired samples, and Dunn’s multiple comparisons test were used.
The Mann-Whitney U-test was used to determine differences be-
tween the 2 groups. For continuous variables, linear correlation and
the nonparametric Spearman rank test were calculated. Values of
Po .05 were considered statistically signiﬁcant.
Results
No adverse reactions were noticed in any of the dogs
after IV administration of repeated doses of rhTSH.
Stimulation Results in Clinically Healthy Dogs
Median (range) T4 and post-TSH T4 concentrations
with 75 and 150mg are shown in Table 1. Calculation of 5
and 95% quartiles with 75 and 150mg rhTSH yielded
post-TSH T4 concentrations of 2.0 and 5.5 mg/dL, and
2.2 and 5.9 mg/dL, respectively. All dogs showed a sig-
niﬁcant increase (P5 .0002) in T4 after administration of
75 and 150mg rhTSH, respectively. However, using
150mg rhTSH led to a signiﬁcantly higher post-TSH T4
concentration (P 5 .003) compared with the lower dose
(Fig 1A). With the exception of 1 dog, all participating
dogs met the stimulation criteria for euthyroidism with
both dosages. The one with an intermediate result had
post-stimulation T4 concentrations of 2.0 and 2.2 mg/dL
with 75 and 150mg rhTSH, respectively.
There was no signiﬁcant correlation between post-
TSH T4 concentrations and the dogs’ body weight
Table 1. T4 and post-TSH T4 concentrations (median
and range) in 18 healthy dogs stimulated with 75 and
150mg rhTSH.
Variable
75 mg rhTSH 150mg rhTSH
Median Range Median Range
T4 (mg/dL) 2.1 1.1–3.0 2.1 1.1–3.3
Post TSHT4 (mg/dL) 3.9 2.0–5.5 4.5 2.2–5.9
T4, thyroxine; rhTSH, recombinant human thyrotropin.
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(r 5 0.31, P 5 .1 with 75 mg TSH; r 5 0.39, P 5 .08
with 150mg TSH). Comparing post-TSH T4 concentra-
tions in dogs weighing 30 kg with those weighing
o30 kg indicated no signiﬁcant differences between the
2 weight categories with either 75 or 150mg TSH (Fig 2).
Stimulation and cTSH Results of Dogs Suspected
to Have Hypothyroidism
Median (range) T4 and post-TSH T4 concentrations
with 75 and 150mg are presented in Table 2; they were
signiﬁcantly lower compared with the healthy control
dogs (P o .001). There was no signiﬁcant difference in
post-TSH T4 concentration with the higher compared
with the lower dose (Fig 1B; P 5 .146). However, using
150mg rhTSH led to a normal test interpretation in 9 of
the 15 dogs according to criteria established in healthy
dogs with 75 mg rhTSH, whereas in the other 6, stimula-
tion still was blunted (2 dogs with intermediate response,
4 dogs with no response). Post-TSH T4 concentrations
and increases in Post-TSH T4 concentrations of the 6
and 9 dogs using both doses are presented in
Table 3 and Table 4, respectively.
Median (range) body weight of the 6 and 9 dogs was
37 kg (31–76 kg) and 30 kg (18–104 kg), respectively.
There was no signiﬁcant correlation between post-TSH
T4 concentrations and the dogs’ body weight (r50.19;
P 5 .5). Four of the 9 dogs in which stimulation was
normal using the higher dose had body weights below
30 kg, and one of them had a body weight below 20 kg.
Median (range) cTSH concentrations in the 15 dogs
were 0.35 ng/mL (0.05–2.2 ng/mL), with 2 dogs having
cTSH concentrations above the reference range.
Excluding 4 dogs from statistical analysis, in which the
2nd stimulation had been performed more than 2 weeks
after the 1st stimulation did not lead to signiﬁcantly
higher post-TSH T4 concentrations using the higher
compared with the lower dose (P 5 .496).
Follow-Up Information on the Dogs, in Which the
2nd Stimulation using the Higher Dose Was Still
Abnormal (n5 6)
Hypothyroidism could be conﬁrmed in all 6 dogs with a
blunted response to the 2nd stimulation based on concur-
rent laboratory ﬁndings (anemia, hypercholesterolemia,
hypertriglyceridemia, increased cTSH concentration) and
follow-up information (3rd TSH-stimulation test, im-
provement or resolution of clinical signs after 4 weeks of
thyroxine supplementation).
Follow-Up Information on the Dogs, in Which the 2nd
Stimulation using the Higher DoseWas Normal (n5 9)
In 5 of the 9 dogs with a normal stimulation using the
higher dose, the owners agreed to a 3rd stimulation using
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Fig 1. Scatter plot representing the inﬂuence of dose of recombi-
nant human thyrotropin (rhTSH) on serum T4 concentrations in
dogs given 75 and 150mg of rhTSH, IV. Before (0 hour) and 6 hours
(6 hours) after stimulation. Median values are indicated by hori-
zontal lines. P values are indicated (P 5) where signiﬁcant
differences were observed; NS, not signiﬁcant; A, results of 18 clin-
ically healthy dogs; B, results of 15 dogs with clinical suspicion of
hypothyroidism.
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Fig 2. Inﬂuence of body weight on post-TSH T4 concentrations in
healthy dogs with 75 and 150mg rhTSH; values of dogs with a body
weighto30 kg (n5 7; circles) are compared with those with a body
weight 30 kg (n5 11; squares). See Figure 1 for remainder of key.
Table 2. T4 and post-TSH T4 concentrations (median
and range) in 15 dogs suspected of having hypothyroid-
ism stimulated with 75 and 150mg rhTSH.
Variable
75 mg rhTSH 150mg rhTSH
Median Range Median Range
T4 (mg/dL) 1.2 0.7–3.5 1.0 0.5–2.0
Post-TSH T4 (mg/dL) 2.0 1.1–4.7 2.6 1.2–3.5
T4, thyroxine; rhTSH, recombinant human thyrotropin.
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the lower dose, which was performed after a median
(range) of 19 (12–24) months after the 1st stimulation.
Post-TSH T4 concentrations were normal in 3 of them
and they were clinically unremarkable with normal lab-
oratory test results. Therefore, hypothyroidism was
excluded. Two of the 3 had received NSAIDS during the
time when the 1st 2 stimulation tests had been performed;
the other had been diagnosed with hypoadrenocorticism
and had received 0.5mg/kg prednisolone q24h in
addition to ﬂudrocortisone. When the 3rd stimulation
was performed, NSAIDS and prednisolone had been
withdrawn.
Two of the 5 dogs had a post-TSH T4 concentration of
1.7mg/dL after the 3rd stimulation with a basal T4 concen-
tration of 0.5 mg/dL (cTSH, 0.27 ng/mL) and 1.3 mg/dL
(cTSH, 0.7 ng/mL), respectively. Nineteen and 23
months previously, post-TSH T4 concentrations using
the higher rhTSH dose had been 2.6 and 3.0mg/dL,
respectively. Both dogs still had recurrent dermatologic
problems and had been treated intermittently with anti-
biotics and glucocorticoids not only during the 1st 2 but
also at the time of the 3rd stimulation. Routine labora-
tory test results were within normal limits, and the
owners decided against levothyroxine supplementation
at that time. Therefore, hypothyroidism could neither be
clearly conﬁrmed nor excluded.
In 4 of the 9 dogs, follow-up information only was
available by telephone contact with the owner or the vet-
erinarian. All 4 dogs had been treated with antibiotics,
glucocorticoids, or both at the time the TSH stimulation
tests had been performed. Another diagnosis had been
made, and the dogs had been treated accordingly. The
owners reported that the dogs were doing well with no
clinical signs and without medication 12 (2 dogs), 21, and
24 months after the 1st stimulation, respectively. Hypo-
thyroidism therefore was considered unlikely.
Overall, based on our follow-up information, hypo-
thyroidism is highly unlikely at least in 7 of the 9 dogs
with a normal 2nd stimulation. In the other 2 dogs, hy-
pothyroidism could neither be clearly conﬁrmed nor
excluded. Differentiation between primary hypothyroid-
ism and nonthyroidal disease therefore was improved by
using the higher rather than the lower dose.
Discussion
The purpose of the present study was to evaluate the
effectiveness of 2 doses of rhTSH in assessing thyroid
function in healthy and suspected hypothyroid dogs. We
showed that in healthy dogs the magnitude of stimula-
tion was signiﬁcantly inﬂuenced by the rhTSH dosage,
inasmuch as they had signiﬁcantly higher post-TSH T4
concentrations using the higher rather than the lower
dose. Although this observation could not be conﬁrmed
in the suspected hypothyroid dogs, using the higher dose
led to a normal test interpretation in the majority of
dogs. The lower dose therefore had resulted in a less than
maximal stimulation in patients without hypothyroidism
and could possibly have led to an inappropriate diagno-
sis of hypothyroidism if the 2nd stimulation had not been
performed.
Most dogs were restimulated within 9 days. However,
in 3 dogs several months had passed between the 1st and
2nd stimulation. In these dogs, a clinical change in the
patient and the withdrawal of the medication may have
inﬂuenced the test result of the 2nd stimulation. It is
highly likely that even the lower dose would have led to a
normal stimulation at that time point. An argument fur-
ther supporting this assumption is the fact that those
dogs with no clinical signs and not receiving medication
had normal post-TSH T4 concentrations at the 3rd stim-
ulation using the lower dose. The TSH-stimulation test
also can be blunted in dogs with nonthyroidal disease or
in dogs treated with glucocorticoids.4,11 However, the
practicing veterinarian can be presented with dogs sus-
pected of having hypothyroidism that are already being
treated with medication at the time of testing or have a
concurrent disease. As indicated by our results, the sup-
pressive effect of drugs or nonthyroidal illness seems to
be less pronounced using a higher dose of TSH. There-
fore, to improve the discriminatory ability of the TSH
stimulation test to differentiate between nonthyroidal ill-
ness and primary hypothyroidism, the higher dose
should be recommended in dogs, in which testing cannot
be delayed.
Interestingly, the responsiveness of the dogs to the
stimulations with 2 different doses was not body weight
dependent. Although in our healthy dogs, post-TSH T4
concentrations were signiﬁcantly higher with the higher
dose, this difference also was unrelated to the dogs’ body
weight. This ﬁnding clearly is an argument against a
weight-related phenomenon. Therefore, a dosage recom-
mendation based on a body weight category (ie, 50 and
Table 3. Post-TSH T4 concentrations (median, range)
at both dosages in 9 and 6 dogs in which stimulation us-
ing the higher dose was considered normal and still
abnormal, respectively.
Post-TSH T4 (mg/dL)
Normal 2nd
stimulation (9 dogs)
Abnormal 2nd
stimulation (6 dogs)
Median Range Median Range
75mg rhTSH 2.2 (1.8–4.7) 1.5 (1.1–2.0)
150mg rhTSH 2.7 (2.6 –3.5) 1.5 (1.2–2.0)
T4, thyroxine; rhTSH, recombinant human thyrotropin.
Table 4. X-fold increase (median, range) of post-TSH
T4 concentrations at both dosages in 9 and 6 dogs in
which stimulation using the higher dose was considered
normal and still abnormal, respectively.
X-fold Increase of
Post-TSH T4
Abnormal 2nd
Stimulation
(9 dogs)
Normal 2nd
Stimulation
(6 dogs)
Median Range Median Range
75mg rhTSH 1.5 (1.3–2.4) 1.4 (0.9–2.9)
150mg rhTSH 2.3 (1.5–2.9) 2.0 (1.8–2.9)
T4, thyroxine; rhTSH, recombinant human thyrotropin.
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100mg rhTSH for body weight below and above 30 kg,
respectively), as has been suggested,10 does not seem to
be reasonable. Alternatively, we had 5 suspected hypo-
thyroid dogs with body weights below 30 kg, in which
only stimulation with the higher dose was considered
normal.
A dose- but not weight-related increase in post-TSH
T4 concentration was already demonstrated in the 1st
study evaluating rhTSH.8 The authors compared stimu-
lation results using 50 and 100mg rhTSH in a group of
healthy Beagle dogs of similar body weight. Although
not statistically signiﬁcant, the higher dose led to higher
post-TSH T4 concentrations. The results of that study,
like ours, indicate that using a higher dose leads to a
higher stimulation, a fact providing evidence that the
maximal stimulation of the thyroid gland has not yet
been reached. Use of a low dose of rhTSH might there-
fore result in less than maximal stimulation and hence
lead to a different test interpretation. Although our re-
sults show that the higher dose of rhTSH resulted in a
greater T4 response especially in dogs, in which thyroid
gland was suppressed by concurrent disease or by medi-
cation, no conclusions on the optimal dose of rhTSH
can be drawn as an actual dose response study was not
performed.
Therefore, the question arises whether criteria for test
interpretation must be adjusted or modiﬁed for each dos-
age, as has been proposed in an earlier study using the
bovine TSH preparation.12 The authors evaluated 2
doses of bTSH in healthy dogs and found a signiﬁcantly
lower response to the low dose of bTSH (1 IU) than to
the high dose (5 IU) of bTSH. Notably, this effect also
was observed to be independent of the dogs’ body
weights. The authors concluded that the lower dose can
be used to perform the test, but they recommended that
criteria for test interpretation should be modiﬁed from
those that are used for the higher dose. Various criteria
for test interpretation can be found in the literature on
using rhTSH.6–9,13 In all but 1 of those studies, criteria
merely have been adapted from earlier experience with
the bovine preparation. Although the bioactivity per mi-
crogram of TSH of the recombinant human preparation
seems to be higher14 compared with that of the bovine
preparation, one could assume that using 75 mg rhTSH
must be considered a low-dose TSH stimulation test, as
suggested by Beale and colleagues for the 1 IU bTSH
dose. A recent study13 suggested that criteria for test
interpretation using rhTSH that were proposed in early
and experimental studies might be too stringent. The au-
thors therefore deﬁned new criteria based on their own
experience but not on systematic testing.
In a previous study, we evaluated rhTSH in 38 healthy
dogs of different breeds6 and calculated reference ranges
for post-TSH T4 concentration as 5, 50, and 95% quan-
tiles. The 5% quantile post-TSH T4 concentration in that
study was 2.5 mg/dL. This value is quite different from
the 5% quantile calculated in the present study of 2.0 and
2.2mg/dL using 75 and 150mg rhTSH, respectively. Com-
paring the ages of the 38 dogs in the earlier study with
those of the 18 healthy dogs in the present study revealed
that the former were signiﬁcantly younger (P 5 .001;
data not shown). Age-related changes in the secretory
capacity of the thyroid gland might be responsible for
this observation, as has been shown for the unstimulated,
physiological T4 concentration.15,16 Reference values in
general, or in our case criteria for test interpretation,
should best be established not only in a healthy popula-
tion but also in a population with an age range in which
the disease is expected to occur. Recalculating the 5%
quantile including all healthy dogs (38 of the previous
study including 18 purpose bred Beagle dogs and 18 of
the present study) resulted in a post-TSH T4 concentra-
tion of 2.2 mg/dL. Excluding the 18 Beagle dogs results in
an even lower post-TSH T4 concentration of 2.0 mg/dL.
Using the low-dose rhTSH stimulation test with the
2.2 mg/dL post-TSH T4 concentration as the criterion
for a normal stimulation leads to a difference in test in-
terpretation compared with the higher dose in only 4 of
the 15 dogs.
The main limitation of our study, but also of most
others evaluating thyroid function, is the lack of a
gold standard with which the true thyroid status of the
dogs can be determined. Approximately 75% of the thy-
roid gland must be destroyed before thyroid hormone
production is diminished.14 Pre- or subclinical hypothy-
roidism at least in some of our healthy but older animals
cannot be deﬁnitely excluded. Evaluating rhTSH tests in
these animals might lead to a less pronounced response in
T4 concentration, which in turn could lead to less strin-
gent criteria for a normal response. In the present study,
dogs were not randomly assigned to receive either the low
or the high dose, which is a bias that could have affected
our results. However, randomization would only have
been feasible in the healthy dogs.
At present, the use of rhTSH in suspected hypothyroid
dogs still necessitates prudence and increased vigilance,
especially in patients with concurrent disease or on
medication. More well-controlled studies are needed
to determine the optimal dosage and possibly also the
optimal criteria for test interpretation in suspected hypo-
thyroid dogs, including those with subclinical hypo-
thyroidism. Future studies should use a gold standard
other than the TSH stimulation test, as has been pro-
posed recently.17
In conclusion, our study demonstrated that using the
higher dose of rhTSH resulted in a higher discriminatory
power with regard to differentiating between primary hy-
pothyroidism and nonthyroidal disease. The magnitude
of stimulation was inﬂuenced by the rhTSH dose but not
by the dogs’ body weight. We recommend the higher
dose of rhTSH for performing a TSH stimulation test in
a diseased animal or an animal on medication, especially
if testing cannot be delayed.
Footnotes
a Thyrogen, Genzyme Genzyme Corporation, Suffolk, UK
b Immulite 1000 Canine Total T4, Diagnostic Products Corpora-
tion—DPC, Los Angeles, CA
c Immulite Canine TSH, Diagnostic Products Corporation—DPC
860 Boretti et al
d SPSS, Statistical Package for the Social Science, Software Packets
for Windows, Version 11, Chicago, IL
eGraphPad PRISM for Windows, Version 3.0, San Diego, CA
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